Evidence map›Paper›PMID 30383455›Full record

ArticleCurrent eye research2019

Intravitreal Delivery of VEGF-A

Olachi J Mezu-Ndubuisi, Yuyuan Wang, Jamee Schoephoerster, Juliana Falero-Perez, Ismail S Zaitoun, Nader Sheibani, Shaoqin Gong

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current eye research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Olachi J Mezu-Ndubuisia Department of Pediatrics , University of Wisconsin-Madison , Madison , WI , USA.ORCID 0000-0002-6930-1747
Yuyuan Wangc Department of Materials Science and Engineering and Wisconsin Institute for Discovery , University of Wisconsin-Madison , Madison , WI , USA.
Jamee Schoephoerstera Department of Pediatrics , University of Wisconsin-Madison , Madison , WI , USA.
Juliana Falero-Perezb Department of Ophthalmology and Visual Sciences , University of Wisconsin-Madison , Madison , WI , USA.
Ismail S Zaitounb Department of Ophthalmology and Visual Sciences , University of Wisconsin-Madison , Madison , WI , USA.
Nader Sheibanib Department of Ophthalmology and Visual Sciences , University of Wisconsin-Madison , Madison , WI , USA.
Shaoqin Gongc Department of Materials Science and Engineering and Wisconsin Institute for Discovery , University of Wisconsin-Madison , Madison , WI , USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI Donna M Peters · 2005 to 2026
$12.6M
Novel Antiangiogenic Peptides for Treatment of Exudative AMDR24EY022883 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEIBANI, NADER · 2013 to 2017
$6.2M
Investigating oxygen metabolism in diabetic retinopathyR01EY026078 · NEI · NORTHWESTERN UNIVERSITY · PI SHEIBANI, NADER, ZHANG, HAO F · 2016 to 2020
$2.3M
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstructionR01HL129785 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG, KENT, K CRAIG · 2016 to 2019
$2.0M
Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling PathwayK25CA166178 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GONG, SHAOQIN - · 2013 to 2017
$994k
NCI NIH HHS K25 CA166178NCI NIH HHS P30 CA014520NEI NIH HHS P30 EY016665NEI NIH HHS R01 EY026078NEI NIH HHS R24 EY022883NHLBI NIH HHS R01 HL129785
6 · The paper itself

Abstract

purposeRetinopathy of prematurity (ROP) is a condition of abnormal retinal vascularization with reduced levels of vascular endothelial growth factor (VEGF) causing vaso-obliteration (Phase I), followed by abnormal neovascularization from increased VEGF (Phase II). We hypothesized that intravitreal pro-angiogenic VEGF-A in microparticle form would promote earlier retinal revascularization in an oxygen-induced ischemic retinopathy (OIR) mouse model. MATERIALS AND

methodsWildtype mice (39) were exposed to 77% oxygen from postnatal day 7 (P7) to P12. VEGF-A

resultsVEGF-A

conclusionsEndogenous retinal VEGF is suppressed in OIR mice. Exogenous intravitreal VEGF-A

Indexed as

Disease Models, AnimalDrug Delivery SystemsAnimalsDrug CarriersEnzyme-Linked Immunosorbent AssayFluorescein AngiographyIntravitreal InjectionsMice, Inbred C57BLMicrospheresOxygenPolylactic Acid-Polyglycolic Acid CopolymerRetinal NeovascularizationRetinal VesselsRetinopathy of PrematurityVascular Endothelial Growth Factor ADrug CarriersOxygenPolylactic Acid-Polyglycolic Acid CopolymerVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseVEGFA protein, humanmicroparticleoxygen-induced retinopathyretinal angiogenesisRetinopathy of prematurityvascular endothelial growth factor

Identifiers

PMID30383455
PMCPMC6661072
OpenAlexW2898850782

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.